AKT1 and lung carcinoma: Ipatasertib’s mechanism of action and initial encouraging clinical results in multiple solid tumors including lung cancer provided additional rationale for inclusion in our studies here to further address the observed increase in p-AKT levels that might play a role in promoting exarafenib resistance apart from the MAPK reactivation we have demonstrated67 (Fig. 4c and Supplementary Fig. 5d).